NDAINTRAVENOUSPOWDERPriority Review
Approved
Sep 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
IDAMYCIN (idarubicin hydrochloride) by Pfizer is dna, inhibiting nucleic acid synthesis, inhibiting topoisomerase ii activity, and producing dna-damaging free radicals. First approved in 1990.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IDAMYCIN (idarubicin hydrochloride) is an anthracycline chemotherapy agent administered intravenously as a powder for reconstitution. It works by intercalating into DNA, inhibiting nucleic acid synthesis, blocking topoisomerase II activity, and generating DNA-damaging free radicals to kill cancer cells. The drug is indicated for hematologic malignancies, primarily acute myeloid leukemia (AML).
LOE Approaching
As LOE approaches, the commercial team is likely contracting; careers on this brand face transition risk unless expansion into new indications or formulations succeeds.
Mechanism of Action
DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IDAMYCIN roles are declining as the product enters LOE; remaining positions focus on maintaining market share against generics and newer therapies rather than growth. This is a mature-stage opportunity suited to professionals experienced in competitive defense and cost-of-goods optimization, not career launch or expansion.
Brand ManagerSales Representative (Oncology)
Worked on IDAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.